CJ to appeal against to Lyrica ruling

CJ Pharm said Wednesday that it will appeal against the latest ruling by Korean Intellectual Property Tribunal that favored Pfizer Korea over the nullification trial of Pfizer’s use patent covering Lyrica (pregabalin).

“This is not the final ruling. We will appeal against the ruling to protect our intellectual properties,” said a CJ official.

He said that CJ has fought against evergreenin...